Baxter Completes Acquisition of Gambro (BAX)

On Friday, healthcare company Baxter International Inc. (BAX) announced that it has finalized its acquisition of medical technology company Gambro AB.

The acquisition will help Baxter’s long term growth in the healthcare industry and will expand its product and therapies portfolio. Baxter will also help grow Gambro’s international exposure by expanding into Latin American and Asia Pacific.

The deal was worth about $3.9 billion and will be included in BAX’s third quarter and full year results.

Robert L. Parkinson, Jr., chairman and chief executive officer of Baxter commented: “The combination of these two respected renal leaders – Baxter and Gambro – will enable Baxter to better serve healthcare providers and patients through a collective offering of innovative renal products and therapies.”

“Together, we will advance the state of dialysis care for patients with kidney disease worldwide.”

Baxter International shares were mostly flat during pre-market trading Friday. The stock is up 5% YTD.